Lung

Lung

Lung was established in the Washington, D.C. suburb of Bethesda, Maryland, at an unconfirmed date, by principals whose identities and wealth origin remain shielded from public record. The firm's refusal to maintain a website or LinkedIn profile distinguishes it from most family offices that use even a minimal storefront to attract co-investment partners or talent. This opacity suggests the capital behind Lung arrived fully formed—possibly from a private business sale, inheritance, or professional-services liquidity event that generated no regulatory filings or press coverage. Without confirmed portfolio disclosures, Lung's investment posture must be inferred from the behaviors of peer single-family offices in the DMV region. Most allocate across public equities, private credit, venture capital fund commitments, and direct real estate—the latter often concentrated in Mid-Atlantic multifamily, industrial outdoor storage, or medical-office assets. If Lung follows the regional pattern, it likely uses a lean internal team supplemented by external managers for niche exposures. The absence of SEC Form ADV filings would be consistent with an office that runs no outside capital and delegates asset management to third-party RIAs. Lung's headcount is unknown, though Bethesda-based family offices with comparable discretion typically employ three to eight professionals, including a chief investment officer, a controller, and one or two analysts sourced from regional endowment or pension backgrounds. No adjacent vehicles—such as a named foundation, real-asset operating company, or donor-advised fund sponsor—appear in IRS or state business-registry records. Recent activity cannot be verified; the firm has generated no detectable transaction announcements, personnel moves, or regulatory changes in the past 24 months. Lung's structural differentiator is its near-complete informational vacuum, which grants it two practical advantages: genuine detachment from sell-side deal flow pressure and the ability to evaluate opportunities without competitors mapping its balance-sheet preferences. The cost is a severely restricted co-investor network, as other family offices and GPs cannot diligence Lung's reputation or decision-making speed. Succession and governance remain entirely opaque—the most significant risk for counterparties is that the entire allocation function resides in one or two unevaluated individuals.